| I-01 Ana Alarcia Lacalle Population pharmacokinetic modelling of levetiracetm in criticaclly ill patients. Influence of creatinine clearance on the probability to attain target concentrations. |
| I-02 Michael Cloesmeijer Capped dosing of desmopressin in Von Willebrand disease: Quantification of the relationship between desmopressin plasma concentration and Von Willebrand factor activity |
| I-03 Alix Démaris Simulation based assessment of different dosing strategies for anti-TNFα monoclonal antibodies in Crohn’s disease patients |
| I-04 Thomas Dumortier A model-based approach to support a label update for flexible dosing of secukinumab in patients with plaque psoriasis |
| I-05 Omar Elkayal Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and exposure in term neonates |
| I-06 Ruben Faelens Building model-informed precision dosing software using R: blueprint for a state-of-the-art development process |
| I-07 Wannee kantasiripitak A multi-model averaging approach improves the performance of model-guided infliximab de-escalation in patients with inflammatory bowel diseases |
| I-08 Simon Koele Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients |
| I-09 Matthias König A physiologically based computational model of indocyanine green liver function tests predicts survival in hepatectomy |
| I-10 Enrica Mezzalana Population pharmacokinetic modelling and simulation of imeglimin in type 2 diabetes patients to support dose recommendations to patients with renal impairment |
| I-11 Robin Michelet Using microdose-based activity measurement to individualise dosing of cytochrome P450 metabolised drugs: a case study with yohimbine and tamoxifen |
| I-12 Sami Ullah Population pharmacokinetics suggests that an intraperitoneal daily dose of 750 mg meropenem is sufficient to treat peritonitis in patients undergoing automated peritoneal dialysis |
| I-14 Niklas Hartung Nonparametric goodness-of-fit testing for parametric covariate models |
| I-15 Sara Carolina Henriques Population pharmacokinetic analysis on data from a bioequivalence study – Effects of hormonal contraceptives on drug exposure |
| I-16 Galina Kolesova Virtual Patient Populations: Comparison of Approaches in Application to QSP Model Of Erythropoiesis |
| I-17 Venelin Mitov A unifying approach to sampling NLME model parameters |
| I-18 Giovanni Smania Conditional distribution modeling for covariates simulation using classification and regression trees methods |
| I-19 Asuka Suzuki Applying parametric bootstrap to generating a distribution of pseudo-objective function value difference for model selection in population pharmacokinetic analysis under time zone-specific nonexistence of observations |
| I-20 Veronika Voronova Exposure-safety analysis for oral GLP-1 analogues: the impact of between-occasion variability in drug absorption on nausea probability |
| I-21 Geraldine Celliere Simulation of first-in-human using an allometrically scaled population mechanistic TMDD model with preclinical monkey data, using the MonolixSuite |
| I-22 Emmanuelle Comets Additional features and graphs in the new npde library for R |
| I-23 Alexandre Duong External evaluation of population pharmacokinetic models of gentamicin in critically ill patients |
| I-24 Mehdi El Hassani Impact of sampling times on the predictive performance of tobramycin population pharmacokinetic models |
| I-25 Ibrahim El-Haffaf Simulation of the impact of unbound fraction variations on the predictive performance of a piperacillin-tazobactam population pharmacokinetic model. |
| I-26 Hanna Kunina Model Averaging Applied to Models With Various Biomarkers Using Multiple Weighting Methods |
| I-28 Fatemeh Aghai Physiologically-based pharmacokinetic modeling of ruxolitinib and posaconazole to predict the clinically relevant CYP3A4 mediated drug-drug interaction |
| I-29 Laura Ben Olivo Pharmacokinetic modeling based on physiology (PBPK): an innovative strategy for optimization of Piperacillin pharmacotherapy |
| I-30 Pavlos Chrysafidis A paradigm shift in oral drug absorption: The rise of physiologically based finite time pharmacokinetic (PBFTPK) models. |
| I-31 Rebekka Fendt Systematic evaluation of personalized physiologically based pharmacokinetic simulations |
| I-32 Angele Fleury A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug–drug–gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol and caffeine |
| I-33 Bart Lammens A Physiologically Based Pharmacokinetic (PBPK) Model of Sildenafil to Predict Exposure in Pregnant Females. What is missing? |
| I-34 Jennifer Lang Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions |
| I-35 Antonina Nikitich Prediction of PD-L1 receptor occupancy in the tumor with PBPK/RO model of PD-L1 inhibitors |
| I-36 Luna Prieto Garcia Simvastatin disposition described by physiologically based pharmacokinetics: Does choice of applied PBPK platform matter? |
| I-37 Javier Reig-López Physiologically Based Pharmacokinetic Model for Atorvastatin: New Insights in Enzymatic and Transport Processes. |
| I-38 Mohammed Saleh Predicting the impact of healthy aging on the brain pharmacokinetic profiles using a translational modeling approach |
| I-39 Ayatallah Saleh Physiologically-based pharmacokinetic (PBPK) modelling to explore the pharmacokinetics (PK) and drug-drug interactions (DDI) potential of midazolam and 1-hydroxymidazolam: the hypothesis of lysosomal trapping |
| I-40 Christina Kovar Physiologically based pharmacokinetic (PBPK) modeling of (E)-clomiphene drug-drug-gene interactions with CYP2D6 and clarithromycin |
| I-41 Jennifer Tardiveau A Physiologically Based Pharmacokinetic model to explore the blood-milk barrier in lactating species: case study with oxytetracycline |
| I-42 Sung-yoon Yang Application of Physiologically Based Pharmacokinetic Modeling and Population Pharmacokinetic Modeling to predict potential Drug-Drug Interaction (DDI) between rivaroxaban and carbamazepine. |
| I-43 Emma Eckernäs Population pharmacokinetic/pharmacodynamic modelling of the psychedelic experience induced by N,N-dimethyltryptamine |
| I-44 Berfin Gülave Opioids distribution in human CNS might be altered due to pain-related increase of BBB permeability. |
| I-45 Heeyoon Jung Equivalent dose prediction of donepezil patch using population pharmacokinetic oral and patch combination model |
| I-46 Tatiana Karelina Quantitative systems pharmacology model of axonal degeneration markers in Alzheimer’s disease |
| I-47 Orestis Papasouliotis Phase III dose selection for evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor: exposure-response analyses from a phase II study in patients with multiple sclerosis |
| I-48 Satoshi Shoji Population Pharmacokinetic Analysis of Tanezumab, a Novel Monoclonal Antibody to Nerve Growth Factor, Following Intravenous or Subcutaneous Administration to Patients with Osteoarthritis or Chronic Low Back Pain in Phase 2b and Phase 3 Studies |
| I-49 Satoshi Shoji Prediction of Free Target Suppression Following Subcutaneous Administration of Tanezumab Based on Target-mediated Drug Disposition Approximation Model |
| I-50 Hanna Silber Baumann Population pharmacokinetic analysis of Satralizumab in NMOSD patients and healthy volunteers. |
| I-51 Jae Eun Ahn Model-Based Meta-Analysis of Triglyceride Reduction in Patients with Hypertriglyceridemia |
| I-52 Alessandro Boianelli Understanding the relationship between in vitro potency, nausea and clinical efficacious concentrations for GLP-1 receptor agonists |
| I-54 Kwan Cheol Pak PK and PD modeling and simulation of GX-H9 in the adult patients with growth hormone deficiency |
| I-55 Daniel Röshammar The population PKPD of unacylated and acylated ghrelin following single rising doses of BI 1356225 in healthy subjects is impacted by the time since last meal |
| I-56 Elrod Chris SAEM in Pumas – A systematic evaluation and benchmarking |
| I-57 Charles Margossian Solving ODEs in a Bayesian context: challenges and opportunities |
| I-58 Andreas Noack Generalized FOCE with Pumas |
| I-59 Monika Twarogowska Implementation of the standard concentration - QTc study using MonolixSuite applications on the example of Dofetilide. |
| I-60 Sergei Vavilov Parameter estimation in nonlinear fixed-effects QSP models: benchmark of optimization methods |
| I-61 Yi Zhang Torsten: Stan functions for pharmacometric applications - Improvements and new R interface workflow |
| I-62 Silvia Grandoni Therapeutic effect of anti-IL6 monoclonal antibodies in the treatment of COVID-19 in adults and multisystem inflammatory syndrome in children using siltuximab as a case study |
| I-63 Charlotte Kern Modeling changes in SARS-CoV-2 variants within-host transmissibility on antiviral drug effect |
| I-64 Timothy Knab A Physiologically-based Pharmacokinetic Modeling Approach to Support Candidate and First in Human Dose Selection for Bamlanivimab |
| I-65 Tarunendu Mapder Antiviral Treatment on SARS-Cov-2 Infected Epithelial Tissue Patch |
| I-66 Aurélien MARC Developing a model of SARS-CoV-2 viral dynamics under monoclonal antibody treatment. |
| I-67 Dirk Jan Moes Towards fixed dosing of tocilizumab in ICU admitted COVID-19 patients; results of an observational population pharmacokinetic and descriptive pharmacodynamic study |
| I-68 Venkatesh Pilla Reddy Application of modelling and simulation in development of an antibody cocktail for the prevention and treatment of COVID-19 |
| I-69 Jingxian Chen Pharmacokinetics Optimization of Phase 2b/3 Study in Infants to Support the Development an RSV Monoclonal Antibody (MK-1654) |
| I-70 Romain Leroux New features in PFIM for optimal design in nonlinear mixed effects models using the S4 object system in R |
| I-71 Claude Magnard Simulx-GUI: a flexible, fast and user-friendly application for simulations |
| I-72 Yuanxi Zou A novel approach to evaluate the design of pediatric PK studies focused on accurate dose selection |
| I-73 Jiyeong Byeon Population PK-PD modeling and simulation of zolpidem to evaluate dosage regimen for sex effect in healthy Korean volunteers |
| I-74 Alejandra Schiavo A QSP model characterizing valproic acid -induced hyperammonemia and the impact of carnitine supplementation |
| I-75 Roberta Bartolucci Development of a genetic algorithm for covariate analysis in population pharmacokinetic models |
| I-76 Iasonas Kapralos Population pharmacokinetic modeling of the complex release kinetics of octreotide LAR: Defining sub-populations by cluster analysis |
| I-78 Ivan Borisov HetaProject – a Single Open Source Platform for Modeling, Simulation and Parameters Estimation in QSP |
| I-79 Jason Chittenden TADAH, a Shiny Application for Producing Report Ready Anti-Drug Antibody (ADA) Tables for MS Word |
| I-80 Ekaterina Mogilevskaya CYTOCON DB as storage of unified data on in vivo human concentrations of cells and molecules in health and disease |
| I-81 Rikard Nordgren Open source software from the Uppsala University Pharmacometrics group |
| I-82 Tarjinder Sahota NMproject new interface: end-to-end script-based NONMEM model development in RStudio |
